WASHINGTON — Scott Gottlieb, President Trump’s nominee to lead the Food and Drug Administration, is taking a softer tone than the White House on the issue of a terminally ill patient’s “right to try” medicines still in the early stages of the agency’s approval process.

“If confirmed, I would commit to ensuring FDA has the right policies and processes in place to appropriately balance individual patients’ needs for access to investigational therapies,” Gottlieb wrote to Senator Patty Murray of Washington, the leading Democrat on the committee deciding Wednesday whether to advance his nomination, “while recognizing the importance of maintaining a rigorous clinical trial paradigm for testing investigational products and demonstrating safety and efficacy.”

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • No political or religious figure should have rhe rright to even suggest on the type of drug to be used in the terminally ill patient. Nor he or she shold have the authority to arbitrarely cut funds for research. This in itself demonstrates his or her total ignorance on the matter.

Your daily dose of news in health and medicine

Privacy Policy